Pediatric Oncology | Specialty

Dr. Roth on Treating AYA Patients With Hodgkin Lymphoma

May 10th 2017

Lisa Giulino Roth, MD, assistant professor of Pediatrics in Medicine, Joan and Sanford I. Weill Department of Medicine , Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treating adolescent and young adult patients with Hodgkin lymphoma.

BCL-2 Inhibitors May Provide Avenue of Attack Against High-Risk Neuroblastoma

April 17th 2017

Investigators at Virginia Commonwealth University Massey Cancer Center discuss the current treatment for children with high-risk neuroblastoma including high-dose chemotherapy, surgery, stem cell transplantation, radiation therapy, isotretinoin, and immunotherapy.

Dr. Gordon on Next Steps With Immunotherapy Research in Osteosarcoma

March 15th 2017

Nancy B. Gordon, MD, assistant professor, Department of Pediatrics, The University of Texas MD Anderson Center, discusses next steps for immunotherapy research in the field of osteosarcoma.

Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue Sarcoma

January 21st 2017

Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.

Preclinical Activity With Olaratumab in Sarcoma

January 6th 2017

Caitlin May, PhD, postdoctoral research scientist at Eli Lilly and Company, discusses preclinical activity with olaratumab (Lynparza) in pediatric sarcoma models.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Dr. Mark W. Kieran on Dabrafenib in Pediatric Patients with BRAF V600-Mutant Disease

November 10th 2016

Mark W. Kieran, MD, PhD, director, pediatric medical neuro-oncology, institute physician associate professor of pediatrics, Harvard Medical School, discusses the first study of dabrafenib in pediatric patients with BRAF V600–mutant disease.

FDA Approves Blinatumomab for Pediatric Acute Lymphoblastic Leukemia

September 2nd 2016

The FDA has granted an accelerated approval to blinatumomab (Blincyto) for the treatment of pediatric and adolescent patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Soft Tissue Sarcoma: Looking Ahead

July 29th 2016

Olaratumab Efficacy in Soft-Tissue Sarcoma

July 29th 2016

Eribulin Mesylate in Soft Tissue Sarcoma

July 29th 2016

Efficacy and Toxicities with Trabectedin in Sarcomas

July 29th 2016

The Role of Trabectedin in Sarcoma Subtypes

July 29th 2016

Recent Approvals in Soft Tissue Sarcoma

July 29th 2016

Sequencing Decisions in Soft Tissue Sarcoma

July 29th 2016

Frontline Approach in Advanced Sarcomas

July 29th 2016

Chemotherapy Sensitivity in Soft Tissue Sarcoma

July 29th 2016

Local Control in Metastatic Soft Tissue Sarcoma

July 29th 2016

Goals of Therapy in Sarcoma

July 29th 2016